Cell Therapy News is an online publication and email newsletter dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Published weekly since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
MaxiVAX SA and Minaris Regenerative Medicine GmbH have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.
Kläsener, K., Jellusova, J., Andrieux, G., Salzer, U., Böhler, C., Steiner, S. N., Albinus, J. B., Cavallari, M., Süß, B., Voll, R. E., Boerries, M., Wollscheid, B., & Reth, M. (2021). CD20 as a gatekeeper of the resting state of human B cells. Proceedings of the National Academy of Sciences, 118(7). https://doi.org/10.1073/pnas.2021342118Cite
Scientists summarize recent studies investigating the involvement of TAMs in immune checkpoint inhibition, tumor vaccines and adoptive cell transfer therapies.
Integrative analysis identified 117 p30-dependent REs associated with 33 strongly down-regulated genes upon p30-knockdown. CRISPR/Cas9-mediated mutational disruption of these genes revealed the RNA-binding protein MSI2 as a critical p30-target.
Heyes, E., Schmidt, L., Manhart, G., Eder, T., Proietti, L., & Grebien, F. (2021). Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA -mutated AML. Leukemia, 1–13. https://doi.org/10.1038/s41375-021-01169-6Cite
Scientists established a procedure for placental HSC transplantation into E11.5 Runx1-deficient mice mated with G1-HRD-Runx1 transgenic mice that had no HSCs in the fetal liver.
Jeon, H., Asano, K., Wakimoto, A., Kulathunga, K., Tran, M. T. N., Nakamura, M., Yokomizo, T., Hamada, M., & Takahashi, S. (2021). Generation of reconstituted hemato-lymphoid murine embryos by placental transplantation into embryos lacking HSCs. Scientific Reports, 11(1), 4374. https://doi.org/10.1038/s41598-021-83652-9Cite
Using T cell bispecific antibodies and chimeric antigen receptors directed against HER2, scientists showed that disruption of interferon-gamma signaling confers resistance to killing by active T lymphocytes.
Arenas, E. J., Martínez-Sabadell, A., Rius Ruiz, I., Román Alonso, M., Escorihuela, M., Luque, A., Fajardo, C. A., Gros, A., Klein, C., & Arribas, J. (2021). Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nature Communications, 12(1), 1237. https://doi.org/10.1038/s41467-021-21445-4Cite
Scientists report the development of novel engineered recombinant adeno‐associated virus vectors that enabled efficient targeting of photoreceptors via less invasive intravitreal administration.
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., Bogedein, J., Wagner, J. E., Priglinger, S. G., Biel, M., Petersen-Jones, S. M., Büning, H., & Michalakis, S. (2021). Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. EMBO Molecular Medicine, n/a(n/a), e13392. https://doi.org/10.15252/emmm.202013392Cite
Therapeutic Solutions International, Inc., reported novel data and filing of a patent application demonstrating that StemVacs™ cells carrying proprietary sequences from the cancer-specific antigen Brother of the Regulator of Imprinted Sites, were able to elicit the generation of T cells capable of selectively killing cancer stem cells.
[Therapeutic Solutions International, Inc. (PR Newswire)]
In November 2020, the FDA granted Regenerative Medicine Advanced Therapy designation for a cellular therapy called AB-205. AB-205 acts promptly to repair injured vascular niches of organs to prevent or reduce severe toxicities in patients who have Hodgkin lymphoma or non-Hodgkin lymphoma undergoing high dose chemotherapy and autologous stem cell transplantation.
[Hackensack University Medical Center (Newswise, Inc.)]
The authors showed that expression of the glucagon-like peptide-1 gene delivered by epidermal stem cells attenuated development and reinstatement of alcohol-induced drug-taking and seeking as well as voluntary oral alcohol consumption.
Researchers report a case of irreversible B cell maturation antigen (BCMA) loss in a patient with multiple myeloma who was enrolled in the KarMMa trial and progressed after anti-BCMA CAR T cell therapy.
Da Vià, M. C., Dietrich, O., Truger, M., Arampatzi, P., Duell, J., Heidemeier, A., Zhou, X., Danhof, S., Kraus, S., Chatterjee, M., Meggendorfer, M., Twardziok, S., Goebeler, M.-E., Topp, M. S., Hudecek, M., Prommersberger, S., Hege, K., Kaiser, S., Fuhr, V., … Rasche, L. (2021). Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nature Medicine, 1–4. https://doi.org/10.1038/s41591-021-01245-5Cite